Revolution Medicines (RVMD) adds $1.65B equity plus $500M in 0.50% convertible notes
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Revolution Medicines, Inc. completed a major equity financing, selling 10,563,381 common shares at $142.00 per share, with underwriters exercising an option for an additional 1,584,506 shares. The company expects net proceeds of about $1,650.4 million from this equity offering.
Concurrently, the company entered into an agreement to sell $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033, with closing expected on April 17, 2026, subject to customary conditions. Both transactions were conducted under an automatic shelf registration and involved standard underwriting terms and indemnification provisions.
Positive
- None.
Negative
- None.
Insights
Revolution Medicines secures large equity and convertible funding that significantly boosts its cash resources.
The company raised substantial capital by selling over 12 million common shares at $142.00 per share, producing expected net equity proceeds of about $1,650.4 million. This represents a sizeable cash inflow that can support pipeline development, commercialization, or general corporate purposes as later defined.
In parallel, it agreed to issue $500,000,000 of 0.50% Convertible Senior Notes due 2033, adding low-coupon debt with potential future equity conversion. The note deal’s closing remains subject to customary conditions, so final funding depends on those being met. Subsequent disclosures after the expected April 17, 2026 closing should clarify final proceeds and detailed terms’ impact on the balance sheet.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Common shares sold: 10,563,381 shares
Underwriters’ option shares: 1,584,506 shares
Equity offering price: $142.00 per share
+5 more
8 metrics
Common shares sold
10,563,381 shares
Equity offering base amount
Underwriters’ option shares
1,584,506 shares
Additional common stock sold via exercised option
Equity offering price
$142.00 per share
Public offering price for common stock
Net equity proceeds
$1,650.4 million
Expected net proceeds after discounts and expenses
Convertible notes size
$500,000,000
Aggregate principal amount of Convertible Senior Notes
Convertible notes coupon
0.50%
Interest rate on Convertible Senior Notes due 2033
Convertible notes maturity
2033
Due date for 0.50% Convertible Senior Notes
Shelf registration file number
333-277640
Automatic shelf registration used for equity offering
Key Terms
automatic shelf registration statement, underwriting agreement, Convertible Senior Notes, aggregate principal amount, +1 more
5 terms
automatic shelf registration statement regulatory
"were offered pursuant to an automatic shelf registration statement (File No. 333-277640)"
An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.
underwriting agreement financial
"entered into an underwriting agreement (the “Equity Underwriting Agreement”) with J.P. Morgan Securities LLC"
An underwriting agreement is a contract where a company selling new stocks or bonds hires financial firms to buy those securities and resell them to investors. It matters because the agreement sets the offering price, number of securities, fees and which party bears the risk if sales fall short—think of it as a promise that the sale will happen and a roadmap investors can use to understand how the new securities reach the market.
Convertible Senior Notes financial
"offer and sale of $500,000,000 aggregate principal amount of the Company’s 0.50% Convertible Senior Notes due 2033"
Convertible senior notes are a type of loan that a company issues to investors, which can be turned into company shares later on. They are called "senior" because they are paid back before other debts if the company runs into trouble. This allows investors to earn interest like a loan but also have the chance to own part of the company if its value rises.
aggregate principal amount financial
"offer and sale of $500,000,000 aggregate principal amount of the Company’s 0.50% Convertible Senior Notes"
The aggregate principal amount is the total amount of money borrowed through a bond or loan that the borrower promises to repay. It’s like the original price tag on a loan or bond, showing how much money is involved in the deal. This number matters because it indicates the size of the debt and helps investors understand the scale of the borrowing.
forward-looking statements regulatory
"includes forward-looking statements, including statements regarding the completion of the Convertible Note Offering"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What equity financing did RVMD complete in April 2026?
Revolution Medicines completed a public equity offering of 10,563,381 common shares at $142.00 per share, plus 1,584,506 additional shares from an underwriters’ option, generating about $1,650.4 million in expected net proceeds after underwriting discounts and estimated expenses.
How much cash does RVMD expect from its April 2026 stock sale?
The company expects net proceeds of approximately $1,650.4 million from its common stock offering. This figure reflects the public sale of primary shares, full exercise of the underwriters’ option, and deductions for underwriting discounts, commissions, and estimated offering expenses borne by the company.
What are the terms of RVMD’s new convertible notes offering?
Revolution Medicines agreed to issue $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033. The notes carry a low 0.50% coupon and senior status, with closing expected on April 17, 2026, subject to customary closing conditions in the underwriting agreement.
When did the RVMD equity offering close and under what registration?
The equity offering closed on April 16, 2026, using an automatic shelf registration statement filed March 4, 2024. A final prospectus supplement dated April 14, 2026, and filed April 15, 2026, set out detailed terms for the common stock sale described in this transaction.
Who underwrote Revolution Medicines’ April 2026 offerings?
J.P. Morgan Securities LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC acted as representatives of the underwriters for both the equity and convertible note offerings. The underwriting agreements include customary representations, covenants and indemnification provisions favoring these underwriting firms.
What risks did RVMD highlight about the April 2026 offerings?
The company noted forward-looking risks including overall market conditions, satisfaction of closing conditions for the convertible notes, and business risks described under “Risk Factors” in the final prospectus supplements and periodic SEC reports, which could cause actual outcomes to differ from expectations.